With a projected end date of November 2023, participants will either take Paxlovid (nirmatrelvir and ritonavir) or a placebo (plus ritonavir) for 15 days — three times longer than the recommended use of Pfizer’s antiviral, which was authorized for emergency use in late 2021. The primary goal is to test for reduction of severe symptoms of long COVID-19.
HHS estimates that anywhere from 7.7 million to 23 million people in the U.S. have long COVID-19, a recent health issue that has more questions than answers. There are no approved treatments for those who have recovered from COVID-19 but report fatigue, brain fog, dyspnea, body aches, and gastrointestinal and cardiovascular issues.
Other research has tested Paxlovid as a potential treatment for long COVID-19 symptoms, but that data has yet to go through peer review.
A secondary endpoint will glean “the correlation of physical activity and biometric parameters” from Apple Watches and blood pressure monitors to analyze symptom severity, according to the entry. Participants with an iPhone 6S Plus or newer will be invited to be included in the substudy.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.